Thursday, June 28, 2018

Nature Reviews Drug Discovery contents July 2018 Volume 17 Number 7 pp 455-527

If you are unable to see the message below, click here to view.
Nature Reviews Drug Discovery

On the Pathway to Discovery, All Signals Are Clear

What if you could get high quality results without the hassle? Our wide range of assay solutions makes it easier to take an orthogonal approach to your cell-based assays, glean more biologically relevant information, and get to breakthroughs faster. Learn More

July 2018 Volume 17, Issue 7

News and Analysis
Research Highlights

BIOPHARMA DEALMAKERSCompany Profiles and Partnering Opportunities

Submit your abstract for the RNA at the Bench and Bedside conference by July 30.

This conference will cover the numerous roles of RNAs and the efforts to translate advances in the basic science into new therapies. It will address the opportunities, current status, and the future of this exciting field. View the draft program for more details.

Remember to register before submitting your abstract.



Translating translation    pp455 - 456
Christopher P. Austin
The term 'translation' has emerged as a dominant concept in biomedical science over the last decade, but confusion around what the term means, and how it differs from translational research and translational science, is common. This article aims to help address this issue by clarifying the distinctions.

News and Analysis


First GPCR-directed antibody passes approval milestone    pp457 - 459
Elie Dolgin

News in Brief

FDA approves Eli Lilly's baricitinib    p460
Asher Mullard

mRNA vaccines get another booster    p460
Asher Mullard

Ebola outbreak prompts experimental drug rollout    p460
Asher Mullard

Biobusiness Briefs

Market watch: Upcoming catalysts in Q3 2018    p461
Karen Nguyen

An Audience With

Amy Abernethy    pp462 - 464
Amy Abernethy, CSO at Flatiron Health, talks about how cleaned up and curated real-world data stands to transform clinical trials, drug regulation, competition in the health-care market and drug prices.

From the analyst's couch

The global landscape of cancer cell therapy    pp465 - 466
Jun Tang, Vanessa M. Hubbard-Lucey, Laura Pearce, Jill O'Donnell-Tormey & Aiman Shalabi
How many cancer cell therapies are being developed? To harmonize efforts in this arena, the Cancer Research Institute has curated a database that includes all cell therapies in development.

Do you have a career question? 

The Naturejobs podcast features one-on-one Q&As, panel discussions and other exclusive content to help scientists with their careers. Hosted on the Naturejobs blog, the podcast is also available on iTunes and Soundcloud. 

Listen today!

Research Highlights


Stroke: Opening the therapeutic window    p467
Sarah Crunkhorn

Cancer: Re-educating tumour-associated macrophages with nanoparticles    p468
Megan Cully

Infectious diseases: The painful path to avoiding the immune system    p469
M. Teresa Villanueva

Lead identification: The importance of residual complexity    p470
Rebecca Kelsey

In Brief

Cancer: Minimizing metastasis    p470
Sarah Crunkhorn

Infectious disease: Alphavirus receptor identified    p470
Sarah Crunkhorn

Autoimmune disease: Aryl hydrocarbon receptor suppresses inflammation    p470
Sarah Crunkhorn

Drug Discovery
JOBS of the week
In Vivo Scientist / Sr Research Associate, PDX Model- Oncology
Postdoctoral Research Fellowship- Drug Addiction / Cognitive Neuroscience
National Institute on Drug Abuse (NIDA)
Postdoctoral Research Scientist
Johns Hopkins University
Postdoctoral Research Associate
Stowers Institute for Medical Research
Postdoctoral Fellow Position
Vanderbilt University Medical Center
More Science jobs from
Drug Discovery
Keystone Symposia: 21st Century Drug Discovery and Development for Global Health
Berlin, Germany
More science events from



Cryo-EM in drug discovery: achievements, limitations and prospects    pp471 - 492
Jean-Paul Renaud, Ashwin Chari, Claudio Ciferri, Wen-ti Liu, Hervé-William Rémigy et al.
Recent technological advances with cryo-electron microscopy (cryo-EM) — a biophysical technique that can be used to determine the structure of biological macromolecules and assemblies — have raised hopes that it might soon become an important tool for drug discovery, particularly for 'intractable' targets that are still not accessible to analysis by X-ray crystallography. This article describes these advances and critically assesses their relevance for drug discovery.

Advances and innovations in haemophilia treatment    pp493 - 508
Rob Peters & Tim Harris
New therapies in development for haemophilia — including gene therapies, proteins with extended half-lives and inhibitors of natural anticoagulants — look poised to change the management of this disease. In this Review, Peters and Harris discuss recent progress, including the hurdles that still need to be overcome in order to translate these advances into routine clinical use.

The promise and challenges of immune agonist antibody development in cancer    pp509 - 527
Patrick A. Mayes, Kenneth W. Hance & Axel Hoos
Co-stimulatory receptors mediate the anticancer immune response. This Review discusses the current efforts in targeting co-stimulatory receptors with agonist antibodies and the landscape of agonist antibodies in clinical development for cancer treatment.

Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours.

Click here to sign up.
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on For event advertising opportunities across the Nature Publishing Group portfolio please contact
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at:
(You will need to log in to be recognised as a registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Springer Nature | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature

No comments: